{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:16:26Z","timestamp":1791274586002,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.purol.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:58:32Z","timestamp":1644393512000},"page":"299-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recommandations du Comit\u00e9 de canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (CC-AFU) pour la bonne pratique des instillations intrav\u00e9sicales de mitomycine C, d\u2019\u00e9pirubicine et de BCG pour le traitement des tumeurs de la vessie n\u2019infiltrant pas le muscle (TVNIM)"],"prefix":"10.1016","volume":"32","author":[{"given":"P.","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Saint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Traxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2022.01.004_bib0225","series-title":"Estimated number of new cases in 2020, worldwide, both sexes, all ages","author":"IARC Cancer Today","year":"2021"},{"key":"10.1016\/j.purol.2022.01.004_bib0230","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"Recommandations fran\u00e7aises du comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u00a0: actualisation 2020\u20132022\u00a0: tumeurs de la vessie","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0235","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1\u00a0and Carcinoma In Situ)\u00a0\u2013\u00a02019\u00a0Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0240","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.purol.2009.06.009","article-title":"Traitement par instillations v\u00e9sicales de BCG et mitomycine C dans les tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: enqu\u00eate de pratique de l\u2019Afu aupr\u00e8s des urologues fran\u00e7ais","volume":"19","author":"Descazeaud","year":"2009","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0245","first-page":"1067","article-title":"Immunotherapie endovesicale\u00a0: le Bacille de Calmette-Guerin","volume":"11","author":"Chopin","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0250","article-title":"Instauration du traitement adjuvant endovesical par epirubicine des tumeurs de vessie n\u2019infiltrant pas le muscle\u00a0: premier retour national d\u2019experience du CC-AFU Vessie","author":"Rollin","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0255","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","article-title":"Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019association fran\u00e7aise d\u2019urologie (CC-AFU) pour la bonne pratique des instillations endov\u00e9sicales de bcg et de mytomycine c dans le traitement des tumeurs de la vessie n\u2019envahissant pas le muscle (TVNIM)","volume":"22","author":"Roupr\u00eat","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0260","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.purol.2012.04.019","volume":"22","author":"Neuzillet","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0265","article-title":"Recommandations des comites de cancerologie (CC-AFU) et d\u2019infectiologie (CI-AFU) de l\u2019Association Fran\u00e7aise d\u2019Urologie pour la prise en charge effets ind\u00e9sirables et complications du bcg","author":"Audenet","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0270","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0275","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1\u00a0bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0280","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2010.12.002","article-title":"Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?","volume":"59","author":"Oosterlinck","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.purol.2022.01.004_bib0290","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit, MITOMYCINE MEDAC 40mg, poudre pour solution intrav\u00e9sicale. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=69855350 Consult\u00e9 le 16\/10\/2021."},{"issue":"5","key":"10.1016\/j.purol.2022.01.004_bib0295","first-page":"CD006885","article-title":"Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1\u00a0bladder cancer","volume":"11","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.purol.2022.01.004_bib0300","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1586\/14737140.4.6.1057","article-title":"Advances in intravesical therapy of urinary bladder cancer","volume":"4","author":"Malmstrom","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.purol.2022.01.004_bib0305","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit, EPIRUBICINE ACCORD 2mg\/mL, solution injectable ou pour perfusion. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=68360453 Consult\u00e9 le 16\/10\/2021."},{"key":"10.1016\/j.purol.2022.01.004_bib0310","unstructured":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit, BCG-MEDAC, poudre et solvant pour suspension intrav\u00e9sicale. Base de donn\u00e9es publique des m\u00e9dicaments. https:\/\/base-donnees-publique.medicaments.gouv.fr\/extrait.php?specid=60973899 Consult\u00e9 le 16\/10\/2021."},{"key":"10.1016\/j.purol.2022.01.004_bib0315","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bju.15413","article-title":"Time interval from transurethral resection of bladder tumour to bacille Calmette-Gu\u00e9rin induction does not impact therapeutic response","volume":"128","author":"Hensley","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.01.004_bib0320","doi-asserted-by":"crossref","first-page":"e8300","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.purol.2022.01.004_bib0325","doi-asserted-by":"crossref","first-page":"e14377","DOI":"10.1111\/ctr.14377","article-title":"The safety and efficacy of Bacillus Calmette-Guerin intravesical therapy in kidney transplant recipients with superficial bladder cancer","volume":"35","author":"Alkassis","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.purol.2022.01.004_bib0330","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-020-00642-1","article-title":"Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study","volume":"20","author":"Hsu","year":"2020","journal-title":"BMC Urol"},{"issue":"Suppl 1","key":"10.1016\/j.purol.2022.01.004_bib0335","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1166-7087(10)70025-7","article-title":"Les vraies contre-indications du BCG dans le traitement des tumeurs de vessie","volume":"20","author":"Neuzillet","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0340","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/00042737-200410000-00012","article-title":"Bacillus Calmette-Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma","volume":"16","author":"Van Outryve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.purol.2022.01.004_bib0345","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.purol.2022.01.004_bib0350","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.01.004_bib0355","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical bacillus Calmette-Gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000477673","article-title":"Safety and efficacy of intravesical bacillus Calmette-Guerin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review","volume":"99","author":"Poletajew","year":"2017","journal-title":"Urol Int"},{"issue":"31","key":"10.1016\/j.purol.2022.01.004_bib0365","first-page":"F121","article-title":"Gestion pratique de l\u2019ECBU au cours des instillations endov\u00e9sicales de Bacille de Calmette et Gu\u00e9rin (BCG) et de Mitomycine C (MMC)","volume":"4","author":"Saint","year":"2021","journal-title":"Prog Urol\u00a0\u2013\u00a0FMC"},{"key":"10.1016\/j.purol.2022.01.004_bib0370","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.purol.2022.01.004_bib0375","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0380","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0385","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.01.004_bib0390","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(01)64936-X","article-title":"Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911","volume":"157","author":"Vegt","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0395","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01302-08","article-title":"Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics","volume":"53","author":"Ritz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.purol.2022.01.004_bib0400","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0410","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3760\/cma.j.issn.0366-6999.20141045","article-title":"Reduced dose of Bacillus Calmette-Gu\u00e9rin versus full dose of Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer after transurethral resection bladder tumor: a meta-analysis of randomized controlled trials","volume":"127","author":"Qin","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.purol.2022.01.004_bib0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/iju.12609","article-title":"Cancer Committee of French Urological Association. Efficacy and tolerance of one-third full dose bacillus Calmette-Gu\u00e9rin maintenance therapy every 3\u00a0months or 6\u00a0months: two-year results of URO-BCG-4\u00a0multicenter study","volume":"22","author":"Pfister","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0425","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0430","unstructured":"SPILF-AFU-SF2H\u00a0\u2013\u00a0R\u00e9vision 2015\u00a0des recommandations de bonne pratique pour la prise en charge et la pr\u00e9vention des Infections Urinaires Associ\u00e9es aux Soins (IUAS) de l\u2019adulte. https:\/\/www.sf2h.net\/publications\/bonne-pratique-prise-charge-prevention-infections-urinaires-associees-aux-soins-iuas-de-ladulte consult\u00e9 le 16\/10\/2021."},{"key":"10.1016\/j.purol.2022.01.004_bib0435","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.01.004_bib0440","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:35:34Z","timestamp":1761114934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708722000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1166708722000112"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.01.004","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations du Comit\u00e9 de canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (CC-AFU) pour la bonne pratique des instillations intrav\u00e9sicales de mitomycine C, d\u2019\u00e9pirubicine et de BCG pour le traitement des tumeurs de la vessie n\u2019infiltrant pas le muscle (TVNIM)","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}